ClinVar Miner

Submissions for variant NM_000059.3(BRCA2):c.971G>A (p.Arg324Lys) (rs397507435)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 7
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000129650 SCV000184448 likely benign Hereditary cancer-predisposing syndrome 2017-09-21 criteria provided, single submitter clinical testing Lines of evidence used in support of classification: In silico models in agreement (benign),Other strong data supporting benign classification
Color RCV000129650 SCV000689220 uncertain significance Hereditary cancer-predisposing syndrome 2018-08-01 criteria provided, single submitter clinical testing
Counsyl RCV000409872 SCV000488877 uncertain significance Breast-ovarian cancer, familial 2 2016-07-12 criteria provided, single submitter clinical testing
GeneDx RCV000589361 SCV000278837 uncertain significance not provided 2016-07-01 criteria provided, single submitter clinical testing This variant is denoted BRCA2 c.971G>A at the cDNA level, p.Arg324Lys (R324K) at the protein level, and results in the change of an Arginine to a Lysine (AGA>AAA). Using alternate nomenclature, this variant would be defined as BRCA2 1199G>A. This variant has not, to our knowledge, been published in the literature as pathogenic or benign. BRCA2 Arg324Lys was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, suggesting it is not a common benign variant in these populations. Since Arginine and Lysine share similar properties, this is considered a conservative amino acid substitution. BRCA2 Arg324Lys occurs at a position where amino acids with properties similar to Arginine are tolerated across species and is not located in a known functional domain (UniProt). In silico analyses predict that this variant is unlikely to alter protein structure or function. Based on currently available information, it is unclear whether BRCA2 Arg324Lys is pathogenic or benign. We consider it to be a variant of uncertain significance.
Integrated Genetics/Laboratory Corporation of America RCV000589361 SCV000695264 uncertain significance not provided 2015-08-31 criteria provided, single submitter clinical testing
Invitae RCV000637477 SCV000758937 uncertain significance Hereditary breast and ovarian cancer syndrome 2018-01-10 criteria provided, single submitter clinical testing This sequence change replaces arginine with lysine at codon 324 of the BRCA2 protein (p.Arg324Lys). The arginine residue is weakly conserved and there is a small physicochemical difference between arginine and lysine. This variant is present in population databases (rs397507435, ExAC 0.03%). This variant has been reported in an individual affected with breast cancer (PMID: 25186627). ClinVar contains an entry for this variant (Variation ID: 141234). Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The lysine amino acid residue is found in multiple mammalian species, suggesting that this missense change does not adversely affect protein function. These predictions have not been confirmed by published functional studies and their clinical significance is uncertain. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Quest Diagnostics Nichols Institute San Juan Capistrano RCV000216915 SCV000600875 uncertain significance not specified 2017-06-21 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.